An investment fund created by Samsung Biologics and Samsung C&T invested $15 million into U.S.-based biotechnology company Senda Biosciences as part of their efforts to foster core technology required to develop next-generation biopharmaceuticals, Samsung Biologics said on Wednesday.
Samsung Biologics said the Life Science Fund, jointly formed by itself and Samsung C&T, decided to invest in Senda Biosciences, recognizing that the U.S. company has secured a superior programmable drug delivery platform.
An investment fund created by Samsung Biologics and Samsung C&T invested $15 million into U.S.-based biotechnology company Senda Biosciences as part of their efforts to foster core technology required to develop next-generation biopharmaceuticals, Samsung Biologics said on Wednesday.
Samsung Biologics said the Life Science Fund, jointly formed by itself and Samsung C&T, decided to invest in Senda Biosciences, recognizing that the U.S. company has secured a superior programmable drug delivery platform.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article